TY  - JOUR
AU  - Müller-Wieland, Dirk
AU  - Leiter, Lawrence A
AU  - Cariou, Bertrand
AU  - Letierce, Alexia
AU  - Colhoun, Helen M
AU  - Del Prato, Stefano
AU  - Henry, Robert R
AU  - Tinahones, Francisco J
AU  - Aurand, Lisa
AU  - Maroni, Jaman
AU  - Ray, Kausik K
AU  - Bujas-Bobanovic, Maja
PY  - 2017
DO  - 10.1186/s12933-017-0552-4
UR  - http://hdl.handle.net/10668/11240
T2  - Cardiovascular diabetology
AB  - Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more closely align with cardiovascular risk than low-density lipoprotein cholesterol (LDL-C). We...
LA  - en
KW  - Alirocumab
KW  - Diabetes
KW  - Mixed dyslipidaemia
KW  - Non-HDL-C
KW  - ODYSSEY
KW  - PCSK9
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Anticholesteremic Agents
KW  - Biomarkers
KW  - Cholesterol
KW  - Clinical Protocols
KW  - Diabetes Mellitus, Type 2
KW  - Humans
KW  - Hyperlipoproteinemia Type V
KW  - PCSK9 Inhibitors
KW  - Proprotein Convertase 9
KW  - Research Design
KW  - Time Factors
KW  - Treatment Outcome
TI  - Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
TY  - research article
VL  - 16
ER  -